HomeCompareFRLN vs DVY

FRLN vs DVY: Dividend Comparison 2026

FRLN yields 30.82% · DVY yields 3.50%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FRLN wins by $113.7K in total portfolio value
10 years
FRLN
FRLN
● Live price
30.82%
Share price
$6.49
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$138.7K
Annual income
$18,790.33
Full FRLN calculator →
DVY
DVY
● Live price
3.50%
Share price
$150.03
Annual div
$5.25
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.1K
Annual income
$437.78
Full DVY calculator →

Portfolio growth — FRLN vs DVY

📍 FRLN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFRLNDVY
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FRLN + DVY cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FRLN pays
DVY pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FRLN
Annual income on $10K today (after 15% tax)
$2,619.41/yr
After 10yr DRIP, annual income (after tax)
$15,971.78/yr
DVY
Annual income on $10K today (after 15% tax)
$297.17/yr
After 10yr DRIP, annual income (after tax)
$372.11/yr
At 15% tax rate, FRLN beats the other by $15,599.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FRLN + DVY for your $10,000?

FRLN: 50%DVY: 50%
100% DVY50/50100% FRLN
Portfolio after 10yr
$81.9K
Annual income
$9,614.05/yr
Blended yield
11.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FRLN right now

FRLN
Analyst Ratings
2
Buy
5
Hold
Consensus: Hold
Altman Z
-16.9
Piotroski
2/9
DVY
No analyst data
Altman Z
307.5
Piotroski
1/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FRLN buys
0
DVY buys
0
No recent congressional trades found for FRLN or DVY in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFRLNDVY
Forward yield30.82%3.50%
Annual dividend / share$2.00$5.25
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$138.7K$25.1K
Annual income after 10y$18,790.33$437.78
Total dividends collected$95.7K$4.0K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: FRLN vs DVY ($10,000, DRIP)

YearFRLN PortfolioFRLN Income/yrDVY PortfolioDVY Income/yrGap
1← crossover$13,782$3,081.66$11,050$349.62+$2.7KFRLN
2$18,716$3,969.20$12,184$361.04+$6.5KFRLN
3$25,063$5,037.57$13,409$372.07+$11.7KFRLN
4$33,122$6,304.80$14,730$382.68+$18.4KFRLN
5$43,228$7,787.05$16,154$392.89+$27.1KFRLN
6$55,752$9,498.01$17,688$402.69+$38.1KFRLN
7$71,103$11,448.37$19,338$412.07+$51.8KFRLN
8$89,726$13,645.43$21,113$421.04+$68.6KFRLN
9$112,099$16,092.82$23,020$429.61+$89.1KFRLN
10$138,737$18,790.33$25,070$437.78+$113.7KFRLN

FRLN vs DVY: Complete Analysis 2026

FRLNStock

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Full FRLN Calculator →

DVYETF

The iShares Select Dividend ETF seeks to track the investment results of an index composed of relatively high dividend paying U.S. equities.

Full DVY Calculator →
📬

Get this FRLN vs DVY comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FRLN vs SCHDFRLN vs JEPIFRLN vs OFRLN vs KOFRLN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.